HER2-Positive Breast Cancer Market

COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the rise in the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HER2-positive breast cancer market. 

Top Impacting Factors:

• Factors that drive the growth of the HER2-positive breast cancer market include the increase in HER2-positive breast cancer cases globally, which is expected to affect the demand for innovative medications for HER2-positive breast cancer therapy. 
• Furthermore, strong immunotherapy adoption and favorable reimbursement are viewed as good indicators for the growth of the HER2-positive breast cancer market.
• The rise in awareness of HER2-positive breast cancer, as well as the increase in healthcare spending globally, is expected to drive the market expansion.
• Major firms are participating in the development of medicines for HER2-positive breast cancer and the introduction of new medications are anticipated to have a substantial impact on the HER2-positive breast cancer market.
• A surge in R&D activities by leading companies to introduce an approved and effective treatment for HER2-positive breast cancer is expected to act as a market driver.
• However, the market for HER2-positive breast cancer is expected to be severely hampered by high treatment costs combined with the discontinuation of late-stage clinical trials.

Market Trends:

New Product Launches to Flourish HER2-Positive Breast Cancer Market

In May 2019, the Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have the residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Key Benefits of Report:

• This study presents the analytical depiction of the HER2-positive breast cancer along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the HER2-positive breast cancer market share.
• The current market is quantitatively analyzed to highlight the HER2-positive breast cancer market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the HER2-positive breast cancer market.
• The report provides a detailed HER2-positive breast cancer market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the HER2-Positive Breast Cancer Market Report:

• Who are the leading market players active in the HER2-positive breast cancer market?
• What current trends will influence the HER2-positive breast cancer market in the next few years?
• What are the driving factors, restraints, and opportunities in the HER2-positive breast cancer market?
• What future projections would help in taking further strategic steps?
• What is HER2-positive breast cancer?
• What is HER2-positive breast cancer market prediction for the future?
• Who are the leading global players in the HER2-positive breast cancer market?
• What are the current trends and predicted trends?
• What are the key benefits of the HER2-positive breast cancer market report?